The impact of family history of preeclampsia and alteration of MMP-13/TIMP-1 balance in the occurrence of preeclampsia

Abstract

Tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) suppresses the activity of matrix metalloproteinase-13 (MMP-13). The MMP-13/TIMP-1 complex has been proposed to be one of the regulators of collagen types I and III turnover in healthy pregnancy. This study is intended to investigate the distribution of serum levels of MMP-13, TIMP-1 and ratio of MMP-13/TIMP-1 in women with preeclampsia (PE) with a family history of preeclampsia. 37 patients with PE were examined, mean age 24.9±6 years and 32 age matched healthy subjects, mean age 24.7±5.4 years. Patients were divided in two subgroups: subjects with family history of PE (n=18); (PE+FHPE) and subjects without family history of PE (n=19); (PE-FHPE). MMP-13 and TIMP-1 levels were measured via enzyme-linked immunosorbent assay (ELISA), while the ratio was calculated. Either MMP-13 or TIMP-1 alone did not exhibit any obvious differences between normal and PE pregnancies. MMP-13/TIMP-1 ratio was statistically significantly higher in PE than healthy pregnant women: 0.2 (0.1÷0.5) vs. 0.065 (0.05÷0.2) (p<0.05). Patients with PE+FHPE showed statistically significantly lower MMP-13/TIMP-1 ratio compared with PE-FHPE 0.085 (0.05÷0.25) vs. 0.22 (0.12÷0.35) (KW=5.71; p=0.02). These results indicate altered balance between MMP-13 and TIMP-1 in PE patients with family history of preeclampsia. Further studies with more precise analysis and genetic methods are needed to elucidate how imbalance between MMP-13 and TIMP-1 contributes to PE susceptibility and pathogenic mechanisms determining preeclampsia development.

Keywords

• matrix metalloproteinase-13
• tissue inhibitor of matrix metalloproteinase-1
• family history of preeclampsia

References

1. 1. American College of Obstetricians and Gynecologists.Hypertension in pregnancy.Report of the American College of Obstetricians and Gynecologists’ task force on hypertension in pregnancy.Obstetrics and gynecology. 2013 Nov; 122(5): 1122-1130.
2. 2. Eiland E, Nzerue C, Faulkner M. Preeclampsia 2012. J Pregnancy.Jul 11 2012, 586578.
3. 3. Prakash J, Ganiger VC. Acute Kidney Injury in Pregnancy-specific Disorders. Indian J Nephrol. 2017; 27(4):258-70.
4. 4. Poon LC.,Nicolaides KH. Early prediction of preeclampsia. Obstet. Gynecol. Int. 2014, 1–11.
5. 5. Pulkkinen M, Lehto M, Jalkanen M, Näntö-Salonen K. Collagen types and fibronectin in the uterine muscle of normal and hypertensive pregnant patients. Am. J. Obstet. Gynecol. 1984; 149: 711–717.
6. 6. Mansell JP, Bailey AJ. Collagen Metabolism. In Encyclopedia of Endocrine Diseases; Martini L, Ed.; Elsevier: Amsterdam, The Netherlands 2004, pp. 520–529.
7. 7. Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG.Alport’s syndrome, Goodpasture’s syndrome, and type IV collagen. N. Engl. J. Med. 2003; 348: 2543–2556.
8. 8. Tryggvason L, Patrakka J.Alport’s Disease and Thin Basement Membrane Nephropathy. In Genetic Diseases of the Kidney; Lifton RP, Somlo S, Giebisch GH, Eds.; Elsevier: Amsterdam, The Netherlands 2009, Chapter 4: pp. 77–96.

9. 9. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure function and biochemistry. Circ. Res. 2003; 92: 827–839.
10. 10. Kim YS, Kim SH, Kang JG, Ko JH. Expression level and glycan dynamics determine the net effects of TIMP-1 on cancer progression. BMB Rep. 2012; 45: 623–628.
11. 11. Creemers EE, Cleutjens JP, Smits JF, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction, a new approach to prevent heart failure? Circ. Res. 2001; 389: 201–210.
12. 12. Morgunova E, Tuuttila A, Bergmann U, Tryggvason K. Structural insight into the complex formation of latent matrix metalloproteinase 2 with tissue inhibitor of metalloproteinase. Proc. Natl. Acad. Sci. USA 2002; 99: 7414–7419.
13. 13. Gross J, Lapiere CM. Collagenolytic activity in amphibian tissues: A tissue culture assay. Proc. Natl. Acad. Sci. USA 1962; 48: 1014–1022.
14. 14. Bourboulia D, Stetler-Stevenson WG. Matrix metalloproteinases (MMPs) and tissue inhibitors ofmetalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin. Cancer Biol. 2010; 20: 161–168.
15. 15. European Society of Cardiology (ESC) Guideline for the management of cardiovascular diseases during pregnancy. European Heart Journal 2018; 39(34): 3165–3241.
16. 16. Eiland E, Nzerue C, Faulkner M. Preeclampsia 2012. J. Pregnancy 2012, 1–7.
17. 17. Pulkkinen MO, Kivikoski AI, Nevalainen TJ. Group I and group II phospholipase A2 in serum during normal and pathological pregnancy. Gynecol. Obstet. Invest. 1993; 36:96–101.
18. 18. Henriksen K, Karsdal MA. Type I Collagen. In Biochemistry of Collagens, Laminins and Elastin Structure, Function and Biomarkers, 2nd ed.; Karsdal MA., Ed.; Elsevier: Amsterdam, The Netherlands 2019; Chapter 1: pp. 1–12.
19. 19. Nielsen MJ, Karsdal MA.Type III Collagen. In Biochemistry of Collagens, Laminins and Elastin Structure, Function and Biomarkers, 2nd ed.; Academic Press: Cambridge, MA, USA, 2019; Chapter 3:pp. 21–30.
20. 20. Karthikeyan VJA, Lane D, Beevers DG, Lip GYH, Blann AD. Matrix metalloproteinases and their tissue inhibitors in hypertension-related pregnancy complications. J. Hum. Hypertens.2012; 27: 72–78.
21. 21. Wang Z, Lu S, Liu C, Zhao B, Pei K, Tian L, Ma X. Expressional and epigenetic alterations of placental matrix metalloproteinase 9 in preeclampsia. Gynecol. Endocrinol. 2010; 26: 96–102.
22. 22. Laskowska M. Altered maternal serum matrix metalloproteinases MMP-2, MMP-3, MMP-9, and MMP-13 in severe early-and late-onset preeclampsia. BioMed Res. Int. 2017, 1–9.
23. 23. Tayebjee M, Karalis I, Nadar S, Beevers DJ, MacFadyen R, Lip GYH. Circulating matrix metalloproteinase–9 and tissue inhibitors of metalloproteinases–1 and –2 levels in gestational hypertension. AJH 2005; 18: 325–329.
24. 24. Luizon MR, Palei ACT, Sandrim VC, Amaral LM, Machado JSR,Lacchini R. Tissue inhibitor of metalloproteinase (TIMP)-1 is a major endogenous inhibitor of matrix metalloproteinase (MMP)-9, which may affect the responsiveness to therapy in hypertensive disorders of pregnancy. Pharmacogenom. J. 2014; 14: 535–541.
25. 25. Gupta M, Chari S. Assessment of matrix metalloproteinase-1 and its tissue inhibitor of metalloproteinase-1 in pre-eclampsia. Int. J. Sci. Study 2016; 3: 70–73.
26. 26. Myers JE, Merchant SJ, MacLeod M, Mires GJ, Baker PN, Davidge ST. MMP-2 levels are elevated in the plasma of women who subsequently develop preeclampsia. Hypertens. Pregnancy 2005; 24: 103–115.
27. 27. Palei AC, Sandrim VC, Cavalli RDC, Tanus-SantosJE. Comparative assessment of matrixmetalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension.Clin.Biochem.2008; 41: 875–880.
28. 28. Ab Hamid J, Mohtarrudin N, Osman M, Asri AA, Hassan WHW, Aziz R. Matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases 1 and 2 as potential biomarkers for gestational hypertension. Singap. Med. J. 2012; 53: 681–683.
29. 29. Kenny LC, Black MA, Poston L, Taylor R, Myers JE, Baker PN,McCowan LM, Simpson NAB,Dekker GA, Roberts CT. et al. Early pregnancy prediction of preeclampsia in nulliparous women, combining clinical risk and biomarkers the screening for pregnancy endpoints (SCOPE) international cohort study. Hypertension 2014; 64: 644–652.
30. 30. Montagnana M, Lippi G, Albiero A, Scevarolli S, Salvagno GL, Franchi M, Guidi GC. Evaluation of metalloproteinases 2 and 9 and their inhibitors in physiologic and pre-eclamptic pregnancy. J. Clin. Lab. Anal. 2009; 23: 88–92.